Table 3. Univariate and multivariate analyses of prognostic factors associated with overall survival.
|
Test subgroup (n=98) |
Validation subgroup (n=222) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
Univariate |
Multivariate |
|
Univariate |
Multivariate |
||||||||
| Variables | HR | 95% CI | P-value | HR | 95% CI | P-value | Variables | HR | 95% CI | P-value | HR | 95% CI | P-value |
| TrkB at the tumour centre |
TrkB at the tumour centre |
||||||||||||
| (High vs low) |
1.08 |
0.82–1.44 |
0.59 |
|
|
|
(High vs low) |
1.98 |
1.24–3.65 |
<0.01 |
1.32 |
0.71–2.74 |
0.39 |
| TrkB at the tumour margin |
TrkB at the tumour margin |
||||||||||||
| (High vs low) |
1.49 |
1.04–2.05 |
0.03 |
1.09 |
0.69–1.66 |
0.69 |
(High vs low) |
3.11 |
1.99–4.63 |
<0.01 |
1.38 |
0.78–2.37 |
0.26 |
| Higher TrkB at the invasive front |
Higher TrkB at the invasive front |
||||||||||||
| (Positive vs negative) |
1.58 |
1.19–2.10 |
<0.01 |
1.24 |
0.89–1.72 |
0.19 |
(Positive vs negative) |
3.18 |
2.21–4.57 |
<0.01 |
2.09 |
1.26–3.53 |
<0.01 |
| Gender |
Gender |
||||||||||||
| (Male vs female) |
1.30 |
0.95–1.75 |
0.09 |
|
|
|
(Male vs female) |
0.77 |
0.49–1.12 |
0.17 |
|
|
|
| Age |
Age |
||||||||||||
| (>70 vs ⩽70) |
1.00 |
0.76–1.33 |
0.98 |
|
|
|
(>68 vs ⩽68) |
1.61 |
1.13–2.35 |
<0.01 |
1.83 |
1.22–2.87 |
<0.01 |
| Tumour size |
Tumour size |
||||||||||||
| (>50 mm vs ⩽50 mm) |
1.15 |
0.86–1.57 |
0.35 |
|
|
|
(>35 mm vs ⩽35 mm) |
1.92 |
1.31–2.96 |
<0.01 |
0.97 |
0.53–1.82 |
0.92 |
| Macroscopic type |
Macroscopic type |
||||||||||||
| (Depressed vs protruded) |
1.49 |
1.10–2.06 |
<0.01 |
1.19 |
0.85–1.71 |
0.31 |
(Depressed vs protruded) |
2.33 |
1.63–3.41 |
<0.01 |
1.14 |
0.68–1.93 |
0.62 |
| Histology 2 |
Histology 2 |
||||||||||||
| (Undifferentiated vs differentiated) |
0.89 |
0.68–1.18 |
0.44 |
|
|
|
(Undifferentiated vs differentiated) |
0.96 |
0.67–1.35 |
0.82 |
|
|
|
| Histology 3 |
Histology 3 |
||||||||||||
| (Diffuse vs intestinal) |
1.20 |
0.91–1.58 |
0.21 |
|
|
|
(Diffuse vs intestinal) |
1.10 |
0.78–1.57 |
0.58 |
|
|
|
| pT |
pT |
||||||||||||
| (T3, 4 vs T1, 2) |
1.99 |
1.27–3.63 |
<0.01 |
1.19 |
0.71–2.77 |
0.55 |
(T3, 4 vs T1, 2) |
2.37 |
1.62–3.62 |
<0.01 |
0.79 |
0.40–1.58 |
0.49 |
| pN |
pN |
||||||||||||
| (Present vs absent) |
2.52 |
1.66–4.28 |
<0.01 |
2.45 |
1.52–4.43 |
<0.01 |
(Present vs absent) |
2.99 |
2.00–4.77 |
<0.01 |
2.18 |
1.19–4.61 |
0.01 |
| Lymphatic invasion |
Lymphatic invasion |
||||||||||||
| (Present vs absent) |
1.62 |
0.90–4.02 |
0.12 |
|
|
|
(Present vs absent) |
2.08 |
1.30–3.82 |
<0.01 |
0.82 |
0.34–1.91 |
0.65 |
| Vascular invasion |
Vascular invasion |
||||||||||||
| (Present vs absent) |
1.80 |
1.09–3.66 |
0.02 |
0.78 |
0.42–1.69 |
0.48 |
(Present vs absent) |
2.40 |
1.65–3.70 |
<0.01 |
0.93 |
0.50–1.87 |
0.83 |
| Liver metastasis |
Liver metastasis |
||||||||||||
| (Present vs absent) |
1.84 |
1.12–2.77 |
0.02 |
1.34 |
0.79–2.11 |
0.26 |
(Present vs absent) |
4.54 |
2.68–7.21 |
<0.01 |
2.75 |
1.59–4.53 |
<0.01 |
| Peritoneal metastasis |
Peritoneal metastasis |
||||||||||||
| (Present vs absent) |
3.39 |
2.24–4.99 |
<0.01 |
3.19 |
1.96–5.19 |
<0.01 |
(Present vs absent) |
3.17 |
2.07–4.68 |
<0.01 |
2.73 |
1.57–4.77 |
<0.01 |
| Other distant metastasis |
Other distant metastasis |
||||||||||||
| (Present vs absent) | 2.40 | 1.06–4.13 | 0.02 | 1.42 | 0.66–2.69 | 0.34 | (Present vs absent) | 3.29 | 1.98–5.08 | <0.01 | 199 | 1.05–3.59 | 0.03 |
Abbreviations: CI=confidence interval; HR=hazard ratio.
Bold indicates a statistically significant.